Last edition
News about "Bachem Reports Strong H1 Results, Plans USD 460 Mi"
Bachem, a leading Swiss manufacturer of peptides and oligonucleotides, reported robust financial results for the first half of 2025 and unveiled plans to invest USD 460 million over the year to expand its global manufacturing footprint.
Bachem Reports Strong H1 Results, Plans USD 460 Mi | 29/07/2025 | By Darshana | 233
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members